Scilex Holding Co (SCLX)
0.86
+0.01
(+1.37%)
USD |
NASDAQ |
May 03, 16:00
0.8495
-0.01
(-1.22%)
After-Hours: 20:00
Scilex Cash from Financing (TTM): 23.58M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 23.58M |
September 30, 2023 | 15.70M |
June 30, 2023 | 47.72M |
Date | Value |
---|---|
March 31, 2023 | -8.16M |
December 31, 2022 | 21.17M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-8.16M
Minimum
Mar 2023
47.72M
Maximum
Jun 2023
20.00M
Average
21.17M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
Sorrento Therapeutics Inc | 246.59M |
Adial Pharmaceuticals Inc | 4.132M |
Precision BioSciences Inc | 5.387M |
Humacyte Inc | 4.507M |
Perspective Therapeutics Inc | 0.785M |